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THE QUALITY OF MANAGED CARE:
EVIDENCE FROM THE MEDICAL
LITERATURE
JOSEPH GOTTFRIED* AND FRANK A. SLOAN**
I
INTRODUCTION
The past decade has seen a proliferation of state laws aimed at modifying
the function of managed care organizations (“MCOs”).1  Reaction to the
increasing prevalence and novel practices of MCOs has prompted passage of
hundreds of state statutes governing everything from direct access to medical
specialists, to minimum coverage standards for maternity stays.2  The federal
government has also taken action on such matters, and the competing “patients’
bills of rights” under consideration in Congress would all expand federal over-
sight of managed care activities.3  Though the true impetus for these legal initia-
tives is debatable, the proponents of “patient protection” measures often cite
concern over the quality—or safety—of managed care as the driving force
behind their legislative efforts.4  Critics contend that MCOs sacrifice high-qual-
ity health care for cost savings and provide inferior medical coverage compared
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1. For the purposes of this paper, and unless otherwise indicated, “MCOs” (or “managed care
organizations”) can refer to health maintenance organizations (“HMOs”), independent practice
associations (“IPAs”), or preferred-provider organizations (“PPOs”).  HMOs can include staff, group,
or network models.
2. See, e.g., Russell Korobkin, The Efficiency of Managed Care “Patient Protection” Laws:
Incomplete Contracts, Bounded Rationality, and Market Failure, 85 CORNELL L. REV. 1, 15-19 (1999)
(tracing the legislative “backlash” against managed care practices); Frank A. Sloan & Mark Hall,
Market Failures and the Evolution of State Regulation of Managed Care, 65 LAW & CONTEMP. PROBS.
169, 184 (Autumn 2002) (documenting the number and kind of state statutes aimed at managed care).
3. See, e.g., JILL A. MARSTELLER & RANDALL R. BOVBJERG, URBAN INST., FEDERALISM, AND
PATIENT PROTECTION: CHANGING ROLES FOR STATE AND FEDERAL GOVERNMENT (1999),
available at http://newfederalism.urban.org/pdf/occa28.pdf (detailing federal actions affecting managed
care and the provisions of federal patient protection proposals).
4. See, e.g., David A. Hyman, Regulating Managed Care: What’s Wrong with a Patient Bill of
Rights, 73 S. CAL. L. REV. 221, 237-44 (2000) (providing numerous examples of public references by
legislators to the supposedly dangerous practices of managed care companies).
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to fee-for-service (“FFS”) plans.5  Horror stories about alleged abuse or neglect
of patients by MCOs have gained wide circulation.6  There are even web sites
devoted to the promulgation of such anecdotal evidence.7  Opponents of man-
aged care have employed these singular tales of terror to advance their legisla-
tive agendas.8
This article examines the empirical evidence, drawn from the medical litera-
ture, pertaining to the safety of managed care practices.  It seeks to ground the
ongoing debate on the medical merits of MCOs in the science of clinical
research.  The article is divided into three major sections.  Part II is a systematic
review of recent literature on the overall quality of MCOs relative to FFS plans,
focusing on clinically important outcome and process measures.  It extends pre-
vious such analyses to the present day.  Part III surveys articles comparing the
performance of generalists and specialists in the latter’s fields of expertise.  It
aims to weigh claims about the alleged risks of “gatekeeping,” a traditional fea-
ture of managed care that has come under increasing criticism.  Part IV analyzes
the medical evidence on early postpartum discharge (“drive-through deliver-
ies”), perhaps the most publicized example of the supposed dangers of managed
care.  Though originating in FFS settings, this practice is associated with MCOs
due to their widespread adoption of short maternal stays.  Finally, the article
renders an evidence-based opinion on the quality of America’s major form of
private health care coverage.
II
QUALITY-OF-CARE PERFORMANCE: MANAGED CARE
VERSUS FEE-FOR-SERVICE
Considerable data on the quality of care in MCOs versus FFS does exist
even though it is conspicuously absent from public debates on the safety of
managed care and the need for more patient protection laws in the post-FFS
era.  Robert Miller and Harold Luft have reviewed much of the early research
on this subject, and in 1994 published the first of two literature analyses on the
topic.9  Examining studies from 1980 through 1993, the investigators found that
MCO members were more likely than FFS plan enrollees to receive recom-
5. For the purposes of this paper, and unless otherwise indicated, “FFS” (or “FFS plans”) could
refer to indemnity insurance, Medicaid, self-pay, Medicare alone, Medicare with supplemental
indemnity insurance, or Medicare/Medicaid.
6. See Hyman, supra note 4, at 237-41.
7. Examples include http://consumerwatchdog.org and http://dranonymous.com, which publish
alleged examples of HMO wrongdoing.  Other sites, such as http://familiesusa.org, solicit stories of
managed care abuse from the public.
8. See Hyman, supra note 4, at 237-41.
9. Robert H. Miller & Harold S. Luft, Managed Care Performance since 1980: A Literature
Analysis, 271 JAMA 1512, 1512-14 (1994) [hereinafter Miller & Luft, Managed Care Performance].
The authors included HMOs and IPAs under managed care, and private indemnity insurance as well as
Medicare (but not Medicaid) under fee-for-service.  Their paper also considered differences in health
care utilization and expenditure between the two systems.
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mended preventive health services.10  They also reported that treatment pro-
cesses and outcomes for a wide range of medical conditions were roughly com-
parable between the two types of coverage.  In 1997, the authors completed a
second narrative review on the subject.11  Considering studies published since
their previous analysis, they concluded that available evidence suggested essen-
tially equivalent quality of care between MCOs and FFS plans.12  They cau-
tioned, however, that almost none of the papers in their review included pri-
mary data past 1992, when cost cutting by MCOs began in earnest.13
In a recent examination of Miller and Luft’s methods, Kip Sullivan criticized
their analyses for failing to control for differences in the level of coverage
between insurance plans.14  He argued that it is misleading to compare “FFS
patients who are insured but have inferior coverage (e.g., no coverage for drugs
and cancer screens) . . . with [MCO] patients who have superior coverage (e.g.,
coverage for drugs and cancer screens).”15  He proposed to exclude from sys-
tematic review those articles failing to adjust their results for differences in cov-
erage levels offered by competing plans.16  Sullivan correctly called attention to
the nature of the “variables” under investigation in individual studies—a point
that will be pursued later in this paper with regard to the expansive meaning of
“fee-for-service.” His ultimate proposal, however, seems misguided.  MCOs
may well be superior to indemnity insurance precisely because of financial
incentives for preventive health care or access to a cheaper formulary.  In health
service research, such distinctive features of systems of care are presumed to
account for differences in research outcomes, and as such represent the focus of
investigation.  They are not confounding factors that require statistical adjust-
ment.
For the present paper, we conducted a systematic review of the recent medi-
cal literature on the quality-of-care performance of MCOs versus FFS plans.
Our main goal was to capture studies based on primary data collected since
1992, which, as Miller and Luft suggested, may be more relevant than earlier
evidence for understanding current managed care.  We sought articles that
10. See id. at 1516.  “In seven observations from six studies, HMO plan enrollees consistently
received more preventive tests, procedures, and examinations . . . or health promotion activities . . .
than did indemnity plan enrollees.”  Id. at 1512-14.
11. Robert H. Miller & Harold S. Luft, Does Managed Care Lead to Better or Worse Quality of
Care?, HEALTH AFF., Sept./Oct. 1997, at 7, 7 [hereinafter Miller & Luft, Does Managed Care Lead].
This time, the authors had to contend with the emergence of PPOs, which they generally grouped with
fee-for-service plans, in accordance with the practice of the majority of their included studies.  Id. at 9.
12. Id. at 13 (“There were equal numbers of statistically significant positive and negative results for
HMO performance, compared with non-HMO plans.”).
13. Id. at 16-17.
14. Kip Sullivan, Managed Care Plan Performance Since 1980: Another Look at 2 Literature
Reviews, 89 AM. J. PUB. HEALTH 1003, 1004 (1999).
15. Id. at 1003.
16. See id. at 1003-04.  For his own re-analysis, Sullivan writes that a “study was excluded if it (1)
reported that the MCP and FFS groups had different levels of coverage, (2) used utilization rates or
some other measure of quality that has been shown to be influenced by differences in insurance
coverage, and (3) did not adjust the results for differences in coverage.”  Id. at 1004.
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examined differences in the rates of medical processes (such as provision of
proven preventive measures, recommended medications, or indicated proce-
dures) or outcomes (such as mortality or morbidity from disease).17  Studies
were included only if they: (1) were published in peer-reviewed journals; (2)
were not cited in Miller and Luft’s 1997 analysis; (3) concerned the American
health care system; (4) examined either processes or outcomes (excluding
patient satisfaction); and (5) had reasonable comparison groups.18  Each of the
final thirty-three studies—including twenty-three retrospective and seven pro-
spective cohort studies, in addition to two surveys and one cross-sectional
analysis—was evaluated for its quality of evidence based on the guidelines for-
mulated by David Naylor and Gordon Guyatt.19
The thirty-three articles are presented in Tables 1-5, grouped by condition
or disease (cardiovascular disease, cancer, geriatrics, pregnancy/pediatrics, and
miscellaneous).  The tables list the types of coverage compared in each study, as
well as its data sources and the variables included in the authors’ multivariate
analysis (if performed).  Before considering the studies as a whole, we discuss
the major findings from each group of articles separately.
A. Cardiovascular Disease
It is not surprising that the largest group of studies looked at cardiovascular
disease, the most common cause of mortality in America (Table 1).  Five of the
articles examined elements in the management of acute myocardial infarction
(“AMI”).20  Steven Soumerai and his colleagues tested the hypothesis that eld-
erly AMI patients in health maintenance organizations (“HMOs”) may suffer
as a result of delayed approval of the use of ambulances and emergency serv-
17. More specifically, we performed a Medline search for English-language articles from 1997 to
2001, linking the subject headings “exp managed care programs” and “fee-for-service plans” (or “fees,
medical”) with the following terms: “exp quality of health care” and “comparative study.”
18. This approach yielded twenty-six relevant articles.  Four additional papers were identified
using a citation search on ISI Web of Science, starting with the above studies and Miller and Luft’s
reviews.  See Miller & Luft, Managed Care Performance, supra note 9; Miller & Luft, Does Managed
Care Lead, supra note 11. Manual searching of the reference lists within pertinent articles produced
three more papers.
19. C. David Naylor & Gordon H. Guyatt, Users’ Guides to the Medical Literature: X.  How to Use
an Article Reporting Variations in the Outcomes of Health Services, 275 JAMA 554, 554-56 (1996).  The
authors’ criteria for the quality of papers on health services include (1) accurate and comprehensive
outcome measures; (2) sensible comparison groups, “similar with respect to important determinants of
outcome (other than the one of interest)”; and (3) multivariate analysis to adjust for any imbalances in
important prognostic factors among the above groups.  Id. at 555.
20. Edward Guadagnoli et al., Appropriateness of Coronary Angiography after Myocardial
Infarction Among Medicare Beneficiaries: Managed Care versus Fee-for-Service, 343 NEW ENG. J. MED.
1460 (2000); Danny McCormick et al., Differences in Discharge Medication After Acute Myocardial
Infarction in Patients with HMO and Fee-for-Service Medical Insurance, 14 J. GEN. INTERNAL MED. 73
(1999); Mark J. Sada et al., Influence of Payor on Use of Invasive Cardiac Procedures and Patient
Outcome After Myocardial Infarction in the United States, 31 J. AM. C. CARDIOLOGY 1474 (1998);
Mary E. Seddon et al., Quality of Ambulatory Care After Myocardial Infarction Among Medicare
Patients by Type of Insurance and Region, 111 AM. J. MED. 24 (2001); Stephen B. Soumerai et al.,
Timeliness and Quality of Care for Elderly Patients with Acute Myocardial Infarction Under Health
Maintenance Organizations vs. Fee-for-Service Insurance, 159 ARCHIVES INTERNAL MED. 2013 (1999).
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ices.21  They found that times to treatment, EKG, and thrombolytic therapy
were almost identical for Medicare beneficiaries enrolled in HMOs and FFS
plans.22  HMO patients were more likely to receive aspirin.23  Dr. Mark Sada and
his colleagues reported that people in non-Medicare MCO and FFS plans had
similar post-AMI mortality at short-term follow-up, though FFS patients more
often underwent indicated coronary angiography than MCO enrollees.24
Edward Guadagnoli and his colleagues also found that FFS bested MCOs in the
rate of indicated angiography after AMI in their study of Medicare beneficiar-
ies.25  In articles on use of recommended medications after hospitalization for
AMI, Dr. Danny McCormick and his colleagues reported equal rates of receipt
of aspirin and beta-blockers by non-Medicare patients in FFS and MCOs,26
while Mary Seddon and her colleagues published similar findings for a Medi-
care population.27
Two studies compared the use of higher-quality (lower-mortality) hospitals
by FFS and MCO patients for coronary artery bypass graft surgery (“CABG”).
Jose Escarce and Mark Pauly observed greater use of such facilities by non-
Medicare HMO enrollees in California, but not in Florida.28  Medicare FFS
patients in Florida, however, were more often admitted to better hospitals than
Medicare HMO members.29  Dr. Lars Erickson and his colleagues found that
people with FFS were more likely than HMO enrollees to receive CABG at a
lower-mortality hospital in New York State.30  This was true for both Medicare
and non-Medicare populations.31  Dr. Nathan Every and his colleagues studied
the treatment of unstable angina, and found that people with managed care
21. Soumerai et al., supra note 20, at 2013.  They also hypothesized, however, that “[s]ome
organizational processes and incentives in HMOs may raise the quality of care for acute conditions,”
citing twenty-four-hour telephone triage systems and institution of treatment protocols and clinical
pathways as examples.  Id.
22. Id. at 2017-18.
23. Id. at 2018.
24. Sada et al., supra note 20, at 1475.  The investigators included preferred-provider organizations
under FFS.  Id.
25. Guadagnoli et al., supra note 20, at 1460.  The authors used stricter criteria than Sada and his
colleagues for “appropriate” angiography, assigning each patient in their study to an intervention class
according to evidence-based guidelines formulated by the American College of Cardiology and
American Heart Association.  Id. at 1461.
26. McCormick et al., supra note 20, at 73.  The investigators restricted their focus to patients with
either commercial indemnity insurance or HMO coverage.  Id. at 74.
27. Seddon et al., supra note 20, at 24.  The authors did observe a higher rate of referrals to cardiac
rehabilitation in FFS settings than in MCO settings.  Id. at 30.
28. Jose J. Escarce & Mark V. Pauly, Health Maintenance Organizations and Hospital Quality for
Coronary Artery Bypass Surgery, 56 MED. CARE RES. & REV. 340, 340 (1999).  The non-Medicare FFS
group in California and Florida included both indemnity insurance and PPO.  Non-Medicare HMO
enrollees were much less likely to use low-quality hospitals in California than their FFS counterparts.
Id. at 348.
29. Id.
30. Lars C. Erickson et al., The Relationship Between Managed Care Insurance and Use of Lower-
Mortality Hospitals for CABG Surgery, 283 JAMA 1976, 1976 (2000).  The mean adjusted mortality at
the lower-mortality hospitals was 2.1%, compared to 3.2% at the higher-mortality hospitals.  Id. at
1977.
31. Id. at 1979.
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more often received guideline-recommended medications than those with
indemnity insurance.32  They observed no difference between these two groups
in the rates of in-hospital AMI or death.33
In sum, MCOs appear to deliver equal or better medical care to cardiac
patients relative to FFS, but equal or possibly worse invasive care (angiography
or CABG).  As to the latter circumstance, Erickson and his colleagues hypothe-
sized that “[f]inancial risk provides a strong incentive for health plans to select
low-priced hospitals,” even when available data on quality militate against the
use of such facilities (for example, for CABG).34  Dr. Sada and his colleagues
suggested that the “aggressive cost-containment measures . . . found in many
HMOs,” which should have “their most pronounced effect on discretionary
procedures,” may also influence payment for nondiscretionary interventions
(for example, indicated coronary angiography).35  Given the attention paid to
invasive procedures such as bypass and catheterization, it is worth noting that
perhaps the single most important intervention in cardiology is the provision of
an aspirin to a patient with a suspected AMI, which is associated with a 23%
relative reduction—and a 2.4% absolute reduction—in the rate of cardiovascu-
lar death at five weeks.36  The finding by Soumerai and his colleagues that HMO
members were more likely than their FFS counterparts to receive aspirin for
AMI37 seems at least as important as Erickson’s discovery of these patients’ dif-
ferential use of lower-mortality hospitals for CABG in New York State.38
32. Nathan R. Every et al., Influence of Insurance Type on the Use of Procedures, Medications and
Hospital Outcome in Patients with Unstable Angina: Results from the GUARANTEE Registry, 32 J. AM.
C. CARDIOLOGY 387, 387 (1998).  The study included both Medicare and non-Medicare populations.
Id. at 388.
33. Id. at 390.
34. Erickson et al., supra note 30, at 1976.
35. Sada et al., supra note 20, at 1478.
36. ISIS-2 Collaborative Group, Randomised Trial of Intravenous Streptokinase, Oral Aspirin,
Both, or Neither Among 17,187 Cases of Suspected Acute Myocardial Infarction: ISIS-2, LANCET, Aug.
13, 1988, at 349 (also concluding that aspirin use in AMI patients is associated with a fifty percent
relative reduction—and a one percent absolute reduction—in the risk of recurrent infarction at five
weeks).
37. Soumerai et al., supra note 20, at 2017.  The odds ratio for receipt of aspirin by HMO members,
compared to FFS patients, was 1.60 (1.07 to 2.41).  Id.
38. Erickson et al., supra note 30, at 1977.  The theoretical absolute reduction in the rate of death
with universal use of lower-mortality hospitals could be as high as 1.1%.  Id.
GOTTFRIED_FMT.DOC 10/02/02  1:47 PM
Page 103: Autumn 2002] QUALITY OF MANAGED CARE 109
GOTTFRIED_FMT.DOC 10/02/02  1:47 PM
110 LAW AND CONTEMPORARY PROBLEMS [Vol. 65: No. 4
GOTTFRIED_FMT.DOC 10/02/02  1:47 PM
Page 103: Autumn 2002] QUALITY OF MANAGED CARE 111
GOTTFRIED_FMT.DOC 10/02/02  1:47 PM
112 LAW AND CONTEMPORARY PROBLEMS [Vol. 65: No. 4
B. Cancer
Studies of cancer treatment and outcomes comprised the next largest group
of articles, in keeping with the disease’s public health importance (Table 2).
Three papers focused on breast cancer.  Arnold Potosky and his colleagues
reported significantly higher survival for Medicare HMO than Medicare FFS
breast cancer patients in California (though not in Washington State).39  HMO
enrollees in both California and Washington State with early-stage disease were
more likely to receive breast-conserving surgery (“BCS”) with adjuvant radio-
therapy.40  Gerald Riley and his colleagues, in a similar study by some of the
same authors, found that members of Medicare HMOs were less often diag-
nosed with late-stage breast cancer than their FFS counterparts, and were more
likely to receive post-BCS radiotherapy.41  In a rare study that distinguished
between precise types of Medicare coverage (supplemental indemnity, group
model HMO, non-group model HMO, and others), Anna Lee-Feldstein and her
colleagues observed no significant differences between HMO and indemnity
breast cancer cases in terms of stage at diagnosis, use of BCS with adjuvant
radiotherapy, or mortality.42  HMOs were in fact superior to FFS when the latter
was defined to include Medicare and Medicare/Medicaid in addition to private
supplemental insurance (a definition employed by Potosky and his colleagues,
among others).43
Results of studies on colorectal cancer were mixed.  Ray Merrill and his
colleagues reported lower all-cause mortality—as well as increased use of rec-
ommended radiotherapy—for Medicare HMO colorectal cancer patients com-
39. Arnold L. Potosky et al., Breast Cancer Survival and Treatment in Health Maintenance
Organizations and Fee-for-Service Settings, 89 J. NAT’L CANCER INST. 1683 (1997) [hereinafter Potosky
et al., Breast Cancer].  Results were adjusted for age, race, education, stage at diagnosis, whether the
cancer was a first primary, and co-morbidity.  The investigators, using nearly identical methods as in
this study, are responsible for three additional articles on cancer reviewed here.  See also Ray M.
Merrill et al., Survival and Treatment for Colorectal Cancer: Medicare Patients in Two Groups/Staff
Health Maintenance Organizations and the Fee-for-Service Setting, 56 MED. CARE RES. & REV. 177
(1999); Arnold L. Potosky et al., Prostate Cancer Treatment and Ten-Year Survival Among Group/Staff
HMO and Fee-for-Service Medicare Patients, 34 HEALTH SERVICES RES. 525 (1999) [hereinafter
Potosky et al., Prostate Cancer]; Gerald F. Riley et al., Stage at Diagnosis and Treatment Patterns
Among Older Women with Breast Cancer: An HMO and Fee-for-Service Comparison, 281 JAMA 720,
720 (1999).
40. See Potosky et al., Breast Cancer, supra note 39, at 1689.  “On the basis of commonly held
assumptions that BCS with adjuvant radiotherapy is associated with a better quality of life and
randomized trial evidence of its equivalent efficacy to mastectomy, many medical professionals have
recommended that BCS plus radiotherapy represents the best quality of care for early stage breast
cancer.”  Id.
41. Riley et al., supra note 39, at 720.  The study sample included over 40,000 breast cancer
patients, eighty-five percent of them in Medicare FFS.  Id. at 721.
42. Anna Lee-Feldstein et al., Breast Cancer Outcomes Among Older Women: HMO, Fee-for-
Service, and Delivery System Comparisons, 16 J. GEN. INTERN. MED. 189, 193-95 (2001).
43. See id. at 194.  Odds ratio for Stage I diagnosis, group model HMO vs. “expanded-definition”
FFS: 1.68 (1.03 to 2.74).  Risk ratio for all-cause mortality, group model HMO vs. “expanded-
definition” FFS: 0.65 (0.44 to 0.98).  Potosky and his colleagues reported a comparable risk ratio for all-
cause mortality of 0.70 (0.62 to 0.79).  Their definition of FFS was expansive to start.  See Potosky et al.,
Breast Cancer, supra note 39, at 1687.
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pared to FFS cases in California and Washington State.44  Cancer mortality was
similar between the two groups.  Richard Roetzheim and his colleagues, how-
ever, in a smaller study from Florida drawing on similar sources of data, found
that non-Medicare FFS patients had lower all-cause mortality than their MCO
counterparts, perhaps due to increased receipt of chemotherapy.45  Medicare
plans differed inconsistently in their use of chemotherapy and radiation.
Two additional articles concentrated on genitourinary cancer.  Considering
data from a single institution in Arizona, Dr. Stephanie Chin and Dr. Keith
Harrigill reported no significant difference in the time to definitive surgical
therapy for 193 FFS and MCO patients with gynecologic malignancies.46  Poto-
sky and his colleagues found that Medicare FFS prostate cancer patients had
better cause-specific survival than HMO cases, though the two groups had
similar rates of all-cause mortality.47
Overall, MCOs (specifically HMOs) appear to offer cancer patients equal or
better rates of high-quality care and long-term survival than FFS.  Yet most of
the evidence for this conclusion comes from studies by one group of investiga-
tors working with data from two states, California and Washington.  Although
the researchers used accurate and comprehensive outcome measures, sensible
comparison groups, and multivariate analysis (following large numbers of
patients for extended periods of time), their articles are subject to criticism on
the grounds of limited external validity.  In each of their papers, Potosky48 and
Merrill49 (though not Riley50) restricted their managed care sample to members
of two of the oldest and best-established HMOs in the country.51  It could be
argued that these benchmark organizations on the West Coast are not represen-
tative of the relatively immature managed care market characteristic of most of
the country.  Still, it would be perverse to claim that managed care is worse than
FFS in treating cancer patients when the best available evidence supports the
opposite conclusion.
44. Merrill et al., supra note 39, at 177.  This is the third study by this group, which favored use of a
large cancer registry and administrative database as its data source.
45. Richard G. Roetzheim et al., Effects of Health Insurance and Race on Colorectal Cancer
Treatments and Outcomes, 90 AM. J. PUB. HEALTH 1746 (2000).  The average length of follow-up is not
reported in the paper, though it was less than three years.  The study period for the article (1994 to
1997) was later than the interval investigated by Merrill and his colleagues (1985 to 1994).
46. Stephanie Chin & Keith M. Harrigill, Delay in Gynecologic Surgical Treatment: A Comparison
of Patients in Managed Care and Fee-for-Service Plans, 93 OBSTETRICS & GYNECOLOGY 922 (1999).
47. Potosky et al., Prostate Cancer, supra note 39, at 525.  The average length of follow-up is not
reported in the paper, though it was less than ten years and probably similar to the length in this
group’s other studies (four to five years).  Id. at 526.
48. See id. at 526; see also Potosky et al., Breast Cancer, supra note 39, at 1684.
49. See Merrill et al., supra note 39, at 180-81.
50. See Riley et al., supra note 39, at 721-22.
51. Lee-Feldstein and her colleagues, whose article appears to validate Potosky’s results, also set
their study in Northern California, where one of these HMOs is a major player.  See Lee-Feldstein et
al., supra note 42, at 190.
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C. Geriatrics
Six important articles52 explicitly examined outcomes for the elderly, a group
that may be particularly vulnerable to the possible restrictions of managed care
(Table 3).53  Sheldon Retchin and his colleagues reported no significant differ-
ence in the survival rates of elderly stroke patients in Medicare MCO and FFS
plans.54  William Getchell and his colleagues found better survival for elderly
individuals hospitalized for syncope (fainting) who belonged to a group-model
HMO.55  Andrew Kramer and his colleagues conducted a cohort study of 429
older stroke victims.56  They observed better short-term recovery of function
among FFS than HMO enrollees, which they attributed to intensive therapy
received at rehabilitation hospitals.57  People with FFS plans were also more
likely than HMO members to reside in the community at one year, despite the
fact that both groups of patients demonstrated equal recovery of function by
this point in time.58
In another prospective study, Bettina Experton and her colleagues found
that “frail” elderly Medicare beneficiaries were more likely to be readmitted to
the hospital—including for “preventable” reasons—if they belonged to a net-
work model HMO rather than a supplemental indemnity plan.59  Jeremy Holtz-
man and his colleagues followed 211 elderly patients discharged from the hospi-
tal after admissions for stroke, congestive heart failure, chronic obstructive
52. Bettina Experton et al., How Does Managed Care Manage the Frail Elderly?  The Case of
Hospital Readmissions in Fee-for-Service Versus HMO Systems, 16 AM. J. PREVENTIVE MED. 163
(1999); Jeremy Holtzman et al., The Effect of HMO Status on the Outcomes of Home-Care After
Hospitalization in a Medicare Population, 46 J. AM. GERIATRICS SOC. 629 (1998); William S. Getchell
et al., A Comparison of Medicare Fee-for-Service and a Group-Model HMO in the Inpatient
Management and Long-Term Survival of Elderly Individuals with Syncope, 6 AM. J. MANAGED CARE
1089 (2000); Andrew M. Kramer et al., Outcome and Utilization Differences for Older Persons with
Stroke in HMO and Fee-for-Service Systems, 48 J. AM. GERIATRICS SOC. 726 (2000); Frank W. Porell
& Helen B. Miltiades, Disability Outcomes of Older Medicare HMO Enrollees and Fee-for-Service
Medicare Beneficiaries, 49 J. AM. GERIATRICS SOC. 615 (2001); Sheldon M. Retchin et al., Outcomes of
Stroke Patients in Medicare Fee-for-Service and Managed Care, 278 JAMA 119 (1997).
53. See, e.g., Miller & Luft, Does Managed Care Lead, supra note 11, at 19.  Though these six
articles focused on “elder care,” the majority of studies in the present review compared various
populations of Medicare beneficiaries.
54. See Retchin et al., supra note 52, at 119.  The authors did report that MCO enrollees were more
likely to be discharged to nursing homes and less likely to be sent to rehabilitation hospitals or units.
The clinical significance of this finding is unclear.  Id.
55. Getchell et al., supra note 52, at 1089.
56. Kramer et al., supra note 52, at 726.
57. Id. at 732.  FFS patients were more often discharged to such specialized facilities.  Id. at 730.
58. See id. at 730-31.
59. See Experton et al., supra note 52, at 163.  The “frail” elderly were defined as patients who
received home health care services prescribed by a physician.  Id. at 164.  “Preventable” readmissions
were identified using both an algorithm (that defined adverse utilization patterns) and a blinded clinical
review.  Id. at 166.  The confidence intervals in the study were wide.  Id. at 169.  Odds ratio of any
readmission: 3.55 with a confidence interval of 1.08 to 11.78.  The odds ratio for preventable
readmissions was significant only with use of the algorithm: 5.82 with a confidence interval of 1.36 to
24.87.  Id. at 169.
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pulmonary disease (“COPD”), or hip fracture.60  People with Medicare man-
aged care and FFS did not differ significantly in their physical functioning or
rates of hospital readmission over the course of one year.61  Finally, Frank Porell
and Helen Miltiades reported lower mortality rates among moderately disabled
Medicare beneficiaries with supplemental insurance than among their counter-
parts with capitated care.62  Their study, which drew from survey data, found no
difference in the annual odds of disablement among the two groups of patients.63
In general, “frail” or disabled elderly appear to do marginally better in FFS
than MCO settings.  Investigators have proposed various explanations for this
observation.  Kramer and his colleagues discussed the financial incentive for
MCOs to discharge disabled patients to subacute facilities rather than costlier
rehabilitation hospitals, as well as the significant cost savings associated with
long-term nursing home placement of frail elders (which may still be less
socially desirable than continued community residence).64  Experton and her
colleagues alluded to “[c]ontractual financial incentives and disincentives” in
HMOs that may lead to inappropriately short hospital stays for seniors as well
as the withholding of necessary home health care.65  Retchin and his colleagues
suggested that “subtle declines” in physical or mental function as a result of
“fewer [MCO] services in acute care and post-acute care settings” may eventu-
ally take their toll on the elderly.66  Whatever the reason, the differences in out-
comes for seniors—though slight—seem real.
60. See Holtzman et al., supra note 52, at 629.
61. See id. at 631-32.  Physical functioning was measured using a weighted scale of activities of daily
living.
62. See Porell & Miltiades, supra note 52, at 615.
63. Id. at 624-28.  The study did find that FFS beneficiaries without supplemental insurance were
(1) more likely than those with such coverage to die within a year; and (2) more likely than those with
either supplemental coverage or capitated care to become disabled or functionally limited.  Id.
64. Kramer et al., supra note 52, at 731-34.  “Because HMOs do not cover the cost of long-term
nursing home care and receive a higher capitated payment for Medicare services provided to nursing
home residents, they have a financial incentive to place costly individuals in nursing homes.”  Id. at 733.
65. Experton et al., supra note 52, at 170.
66. Retchin et al., supra note 52, at 122-24.
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D. Pregnancy and Pediatric Disease
Six articles examined processes and outcomes for pregnancy and pediatric
disease (Table 4).  Michael Klinkman and his colleagues reported that MCOs
and FFS were equally good at providing high-quality prenatal care to expectant
mothers.67  Denise Oleske and her colleagues studied over 500,000 singleton
deliveries in California and Florida and found no significant differences
between MCO and Medicaid FFS plans in the rates of serious maternal adverse
events.68  Oleske co-authored another paper that examined adverse pregnancy
outcomes (both maternal and neonatal) in California.69  Women in Medicaid
MCOs had a lower likelihood of delivering a low-birthweight baby than moth-
ers with Medicaid FFS.70
Two single-institution studies focused on children with appendicitis.  Stuart
O’Toole and his colleagues reported that pediatric patients with MCO and FFS
coverage had similar durations of symptoms, times until surgery, and rates of
appendiceal perforation.71  Vincent Adolph and Kenneth Falterman found a
lower rate of late appendicitis in children in MCOs compared to those with
indemnity insurance.72  In a cross-sectional study of routine pediatric screening
from New York City, Karla Hanson and her colleagues discovered that children
enrolled in Medicaid capitated care plans were more up-to-date on their immu-
nizations and anemia testing than their counterparts in Medicaid FFS.73
At least in this small number of studies, managed care has not been shown
to endanger the lives of pregnant women or their children.  The issue of early
discharge after delivery—a topic that does not clearly oppose MCOs and fee-
for-service—will be addressed below.
67. Michael S. Klinkman et al., The Effects of Insurance Coverage on the Quality of Prenatal Care,
6 ARCHIVES FAM. MED. 557 (1997).  The investigators developed their own set of evidence-based,
prenatal care guidelines for the purposes of the study using input from faculty physicians at their
institution.
68. Denise M. Oleske et al., Effect of Medicaid Managed Care on Pregnancy Complications, 95
OBSTETRICS & GYNECOLOGY 6 (2000) [hereinafter Oleske et al., Effect of Medicaid].  The authors
considered rates of maternal death, cardiac arrest, excessive blood loss, anesthesia complications,
lacerations to the perineum, and eclampsia.
69. Denise M. Oleske et al., A Comparison of Capitated and Fee-for-Service Medicaid
Reimbursement Methods on Pregnancy Outcomes, 33 HEALTH SERVICES RES. 55 (1998) [hereinafter
Oleske et al., A Comparison].  Like Oleske’s later effort, the study employed an administrative
database and considered only MCOs that capitated care. See Oleske et al., Effect of Medicaid, supra
note 68.
70. Oleske et al., A Comparison, supra note 69, at 60.
71. Stuart J. O’Toole et al., Insurance-Related Differences in the Presentation of Pediatric
Appendicits, 31 J. PEDIATRIC SURGERY 1032 (1996).  The study considered 202 histologically
confirmed cases of acute appendicitis.
72. Vincent R. Adolph & Kenneth W. Falterman, Appendicitis in Children in the Managed Care
Era, 31 J. PEDIATRIC SURGERY 1035 (1996).  The MCO group had a statistically nonsignificant lower
rate of complications as well.
73. Karla L. Hanson et al., The Transition from a Medicaid Fee-for-Service to Managed Care
Among Private Practitioners in New York City: Effect on Immunization and Screening Rates, 2
MATERNAL & CHILD HEALTH J. 5 (1998).
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E. Miscellaneous
The final studies in this review compared managed care and FFS on a mis-
cellany of process and outcome measures (Table 5).  Michael Ward and his
colleagues prospectively followed 182 patients with rheumatoid arthritis over
ten years: 125 with indemnity insurance and 57 in MCOs.74  They reported that
“[a]verage global arthritis status scores, pain scores, and functional disability
scores were closely comparable in the two groups.”75  Robin Weinick and Karen
Beauregard concluded from surveys of nonelderly, privately insured women
that MCOs were superior to indemnity plans in the provision of female preven-
tive screening services in 1987, but not in 1992 (when they were equivalent).76
Drawing on interview data from the Medical Outcomes Study, Paul Lee and his
colleagues found that diabetic patients in MCOs and FFS were equally likely to
have used ophthalmic services in the preceding six months.77
In a unique prospective study on substance abuse, Arthur Alterman and his
colleagues observed that alcohol- and cocaine-dependent people with Medicaid
FFS and HMO coverage had similar addiction severity scores more than six
months after inpatient treatment.78  In another intriguing study, Kelly Kyes and
her colleagues followed injured workers from Washington State enrolled in
indemnity and pilot managed care plans.79  The two groups of patients were
similar at six weeks and six months on a number of outcome measures, includ-
ing freedom from bodily pain and upper-body mobility.80  Wilson and his col-
leagues reported that the physical functioning of AIDS patients in fee-for-serv-
ice and HMO settings was comparable at four months of follow-up.81
74. Michael M. Ward et al., Long-term Health Outcomes of Patients with Rheumatoid Arthritis
Treated in Managed Care and Fee-for-Service Settings, 25 J. RHEUMATOLOGY 641 (1998).
75. Id. at 641.
76. Robin M. Weinick & Karen M. Beauregard, Women’s Use of Preventive Screening Services: A
Comparison of HMO versus Fee-for-Service Enrollees, 54 MED. CARE RES. REV. 176 (1997).  Process
measures included Pap smears and breast exams provided to patients in the past year, and all
mammograms ever provided to patients.
77. Paul P. Lee et al., A Comparison of Self-Reported Utilization of Ophthalmic Care for Diabetes
in Managed Care versus Fee-for-Service, 18 RETINA 356 (1998).
78. Arthur I. Alterman et al., Comparison of Outcomes by Gender and for Fee-for-Service versus
Managed Care: A Study of Nine Community Programs, 19 J. SUBSTANCE ABUSE TREATMENT 127
(2000).  The addiction severity index used in the study was a composite of severity scores from seven
different “problem areas,” including medical, legal, and psychiatric domains.  Id. at 128-29.  The HMO
capitated care.  Id. at 133.
79. Kelly B. Kyes et al., Evaluation of the Washington State Workers’ Compensation Managed Care
Pilot Project I: Medical Outcomes and Patient Satisfaction, 37 MED. CARE 972 (1999).  The Washington
State Department of Labor and Industries selected two managed care organizations (an HMO and
PPO) to provide care for occupational injuries and diseases.
80. See id. at 979.  The managed care patients were, however, significantly less satisfied with their
overall treatment at six weeks, though not at six months.
81. Ira B. Wilson et al., Costs and Outcomes of AIDS Care: Comparing a Health Maintenance
Organization with Fee-for-Service Systems in the Boston Health Study, 17 J. ACQUIRED IMMUNE
DEFICIENCY SYNDROME 424 (1998).  This was another prospective study using interviews as well as
chart reviews.
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F. Summary
What Miller and Luft previously concluded about the quality of MCOs care,
compared to that of FFS,82 continues to be true: The best available evidence
does not demonstrate the clear superiority of one system over the other.  If
MCOs appear better at medically managing unstable angina,83 FFS seems supe-
rior at assuring the appropriate use of coronary angiography.84  Should the
worse outcomes for elderly stroke victims in MCOs be of concern,85 so should
the shorter survival time of breast cancer patients with FFS.86
There are two important caveats to this general assertion of equivalence,
both of which undermine the position of managed care.  First, the MCO popula-
tion in many important studies tended to be younger and better educated than
the FFS cohort.87  The studies’ investigators all employed risk-adjustment meth-
ods to control for these significant baseline differences between comparison
groups.  They could not adjust, however, for important prognostic factors of
which they were ignorant, or which were not measured and recorded (accu-
rately or inaccurately) in their data sources.88  One could speculate that the
actions of these silent confounders would bias the studies in favor of MCOs,
with their more youthful, educated, and probably healthier populations.  Unfor-
tunately, there were no randomized studies in this review to distribute the
unknown factors in an unbiased manner.89
The second caveat pertains to the types of coverage compared in the arti-
cles.  Tables 1-5 reveal the multiple permutations of payment methods opposed
in the studies.  Perhaps most worrisome for the purposes of this review—which
really seeks to compare the performance of indemnity-type insurance plans
with that of MCOs—is the possible inclusion of Medicaid and self-pay patients
82. See Miller & Luft, Managed Care Performance, supra note 9, at 1516; see also Miller & Luft,
Does Managed Care Lead, supra note 11, at 13.
83. See Every et al., supra note 32, at 387.
84. See Guadagnoli et al., supra note 20, at 1460.
85. See Kramer et al., supra note 52, at 726.
86. See Potosky et al., Breast Cancer, supra note 39, at 1683.
87. For example, the mean age of MCO patients in every study was sixty-one, compared to sixty-
seven for FFS subjects.  Every et al., supra note 32, at 389.  Only thirty-three percent of the HMO
breast cancer patients in the Potosky study were older than seventy-five, compared to forty-six percent
of the fee-for-service patients.  Potosky et al., Breast Cancer, supra note 39, at 1685.  In the Merrill
study, thirty-six percent of HMO members in Washington State were in the highest quartile of
education level, compared to twenty-four percent of the FFS population.  Merrill et al., supra note 39,
at 183.  MCO stroke patients in both the Retchin and Kramer studies were more often married, with an
“able and willing caregiver.”  See Retchin et al., supra note 52, at 121; see also Kramer et al., supra note
52, at 730.
88. See Naylor & Guyatt, supra note 19, at 556 (discussing risk adjustment methods and the
benefits of randomization).
89. Indeed, only seven of the cohort studies in this series were even conducted in a prospective
fashion.
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in the FFS category as defined in numerous papers.90  Studies—including ones in
this review—have shown inferior outcomes for people with Medicaid or no cov-
erage compared with privately insured persons.91  Managed care may look even
better when compared to FFS if the latter includes patients with public or no
insurance.  It should be stated, however, that MCOs did outperform indemnity
plans outright in several studies.92
A final point about the articles in this review concerns their sources of infor-
mation.  As Tables 1-5 indicate, at least one-third of the papers relied heavily
on administrative databases: sets of coded diagnoses, procedures, and patient
demographics abstracted by technicians from medical records for reimburse-
ment and planning purposes.  In their article on health services research, Naylor
and Guyatt cited a number of studies that examined the sensitivity and specific-
ity of such sources.93  All raised serious doubts about the completeness and
accuracy of these databases, which researchers often favor because of their
large sample sizes, longitudinal records, and ease of use.94  Collectively, they call
into question the ability of many studies in this review to control for even obvi-
ous and proven prognostic factors, such as the baseline difference in systolic
blood pressure between groups of AMI patients with its known effect on mor-
90. Twenty of the thirty-one articles failed to mention “private” or “indemnity” insurance (primary
or supplemental) among their Medicare or non-Medicare FFS populations.  Some papers explicitly
reported Medicaid or self-pay patients among their FFS sample.
91. For example, Medicaid patients in the Sada study were less likely to undergo nondiscretionary
angiography, and more likely to suffer adverse events after AMI, than enrollees in indemnity or HMO
plans; uninsured individuals also had lower rates of indicated invasive procedures.  Sada et al., supra
note 20, at 1476-78.  In the Lee-Feldstein study, breast cancer cases with Medicare/Medicaid were less
often diagnosed with Stage 1 disease and had higher all-cause mortality than patients with private
insurance (either FFS or MCO).  Women with Medicare alone also had significantly higher all-cause
and breast cancer mortality.  Lee-Feldstein et al., supra note 42, at 193-95.  Children with Medicaid and
acute appendicitis in the O’Toole study had significantly higher rates of appendiceal perforation than
patients with indemnity insurance or HMO coverage (44%, 23%, 27%).  O’Toole et al., supra note 71,
at 1033.
92. See, e.g., Adolph & Falterman, supra note 72, at 1035; Escarce & Pauly, supra note 28, at 340;
Every et al., supra note 32, at 387.
93. See, e.g., James G. Jollis et al., Discordance of Databases Designed for Claims Payment versus
Clinical Information Systems: Implications for Outcomes Research, 119 ANNALS INTERNAL MED. 844
(1993).  The authors compared insurance claims information with prospectively collected data from a
cardiac disease registry for almost 13,000 consecutive patients undergoing coronary angiography.  Id. at
847.  They found that the claims data identified only thirty-nine percent of clinically important
conditions recorded in the registry, including hypertension, congestive heart failure, and tobacco use.
See also Edward L. Hannan et al., Clinical versus Administrative Data Bases for CABG Surgery, 30
MED. CARE 892 (1992) (comparing a cardiac surgery registry and administrative data set in New York
state); David J. Malenka et al., Using Administrative Data to Describe Casemix: A Comparison with the
Medical Record, 47 J. CLINICAL EPIDEMIOLOGY 1027 (1994) (finding that claims-based data often
underestimated the comorbidity of prostate cancer patients as determined by detailed chart reviews,
which were better at controlling for casemix).  The chance-adjusted rate of agreement between the two
systems, for variables such as hypertension, congestive heart failure, and diabetes, ranged from 0.01 to
0.17 to 0.38.  Id. at 896.  The only kappa values above 0.50 in the study were for in-hospital death,
female sex, black race, and PTCA crash.  Id. at 896.  A logistic regression model derived from the
registry contents was significantly better at predicting hospital mortality rates than one founded on
claims information.  Id. at 898-901.
94. See Jollis et al., supra note 93, at 844.
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tality rates.95  Insensitive, inaccurate information in a paper does not “help”
either MCOs or FFS.  Instead, it casts a study’s entire findings under a general
cloud of suspicion.  Though the most recent evidence suggests that MCOs and
FFS care for Americans equally well, the randomized trials to prove it—with
strictly defined comparison groups and prospectively collected primary data—
remain undone.
III
QUALITY-OF-CARE PERFORMANCE: GENERALISTS VERSUS SPECIALISTS
If there is one feature of managed care that is most often cited as an exam-
ple of the dangerous, bottom-line mentality of MCOs, it is gatekeeping: the
requirement that enrollees obtain specialist referrals from “PCPs” (primary
care physicians).  While MCOs maintain that this policy limits the inappropriate
use of resources, critics assert that any potential restriction of access to experts
poses a threat to patients’ health.96  Let us assume, for the sake of argument,
that MCO members with “specialist” diagnoses do in fact see fewer consultants
than their FFS counterparts.  It is still questionable whether the critics are
medically justified in their opposition to gatekeeping, that is, whether the doc-
tors who serve as most PCPs—family physicians (“FPs”), internists, and general
practitioners (“GPs”)—do indeed provide worse “expert” care than specialists
themselves.  To try to resolve this issue, we performed a systematic review of
articles on the quality-of-care performance of generalists versus specialists.  We
conducted separate searches for three common medical consultants: cardiolo-
gists, endocrinologists, and gynecologists.97
A. Cardiologists
The largest group of studies focused on cardiologists and management of
coronary artery disease (“CAD”) and congestive heart failure (“CHF”).  A sys-
tematic review of much of this literature, by Alan Go and his colleagues, was
performed in 2000.98  The authors examined twenty-four articles published
between 1980 and 1997.99  Overall, this research demonstrated that cardiologists
adhered to evidence-based guidelines more often than generalists.  In particu-
lar, specialists were more likely to prescribe recommended medications in the
95. See Kerry L. Lee et al., Predictors of 30-Day Mortality in the Era of Reperfusion for Acute
Myocardial Infarction, 91 CIRCULATION 1659 (1995) (identifying significant predictors of death for
AMI patients, including preexisting conditions such as hypertension and diabetes).
96. See, e.g., MARSTELLER & BOVBJERG, supra note 3, at 5 (discussing aspects of utilization
management by MCOs).
97. All studies appeared in peer-reviewed journals, focused on physicians in the United States, and
employed either processes or outcomes as endpoints.
98. Alan S. Go et al., A Systematic Review of the Effects of Physician Specialty on the Treatment of
Coronary Disease and Heart Failure in the United States, 108 AM. J. MED. 216 (2000).
99. See id. at 217.  Eight of the twenty-four were physician surveys about knowledge of cardiac
disease and (self-reported) practice.  More interestingly, from a quality-of-care perspective, fourteen
studies described actual practice patterns and six studies reported clinical outcomes.  Id.
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setting of an acute myocardial infarction (“AMI”) or a CHF exacerbation.100
Several studies also revealed that patients treated by cardiologists—for either
AMI or CHF—had lower rates of mortality and hospital readmission than those
followed by generalists.101  Go and his colleagues noted, however, that these dif-
ferences in short- and long-term outcomes between specialties were slight.102
Papers published since Go’s review have generally affirmed its conclusions.
Three large studies found that cardiologists employed guideline-supported
therapies for AMI more frequently than generalists.103  One of these articles also
reported slightly better survival rates for AMI patients managed by specialists,104
as did another study that attributed this result to the higher caseloads of cardi-
ologists.105  Andrew Auerbach and his colleagues observed improved survival
rates among heart failure patients treated by specialists,106 though two other arti-
cles found no difference in mortality (or readmission) rates between the CHF
cases of cardiologists and generalists.107  Randall Stafford and David Blumenthal
concluded from survey data that heart doctors provided cardiovascular disease
prevention services (especially cholesterol counseling and prescription of lipid-
lowering agents) more often than internists or FPs.108
The studies cited by Go and his colleagues and the more recently published
research suffer from many of the same methodological weaknesses discussed in
the previous section.  All but one were observational in nature, and all but two
were retrospectively designed.109  Investigators made liberal use of large, admin-
istrative databases.  Though multivariate analyses abound in these articles, so
do potential biases, inaccuracies, and confounding factors.  Discussing just one
limitation, Go and his colleagues wrote that “[d]ifferent types of patients see
100. Id. at 221 (“There were small differences in the use of medical therapies for myocardial
infarction that favored cardiologists.”).
101. Id.
102. Id.
103. See Jersey Chen et al., Care and Outcomes of Elderly Patients with Acute Myocardial Infarction
by Physician Specialty: The Effects of Comorbidity and Functional Limitations, 108 AM. J. MED. 460
(2000); Sumit R. Majumdar et al., Influence of Physician Specialty on Adoption and Relinquishment of
Calcium Channel Blockers and Other Treatments for Myocardial Infarction, 16 J. GEN. INTERNAL
MED. 351 (2001); Donald J. Willison et al., Consultation Between Cardiologists and Generalists in the
Management of Acute Myocardial Infarction: Implications for Quality of Care, 158 ARCHIVES
INTERNAL MED. 1778 (1998).
104. Chen et al., supra note 103, at 460.
105. See Ira S. Nash et al., Generalist versus Specialist Care for Acute Myocardial Infarction, 83 AM.
J. CARDIOLOGY 650 (1999).
106. Andrew D. Auerbach et al., Resource Use and Survival of Patients Hospitalized with Congestive
Heart Failure: Differences in Care by Specialty of the Attending Physician, 132 ANNALS INTERNAL
MED. 191 (2000).
107. See Kishore J. Harjai et al., Effects of Caregiver Specialty on Cost and Clinical Outcomes
Following Hospitalization for Heart Failure, 82 AM. J. CARDIOLOGY 82 (1998); Edward F. Philbin &
Paul L. Jenkins, Differences Between Patients with Heart Failure Treated by Cardiologists, Internists,
Family Physicians, and Other Physicians: Analysis of a Large, Statewide Database, 139 AM. HEART J.
491 (2000).
108. Randall S. Stafford & David Blumenthal, Specialty Differences in Cardiovascular Disease
Prevention Practices, 32 J. AM. C. CARDIOLOGY 1238 (1998).
109. As mentioned earlier, such cohort studies are susceptible to a wide range of problems, such as
confounding and selection bias, which randomization (in particular) tends to minimize.
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different types of physicians—a form of selection bias that often favors the out-
comes of cardiologist-treated patients, who tend to be younger and have fewer
comorbid conditions.”110  At the same time, they noted that “there have not
been any studies that reported patients treated by generalists had more appro-
priate treatment or better outcomes than patients treated by cardiologists.”111  In
general, heart specialists do appear to care for the heart better than other doc-
tors.
B. Endocrinologists
Comparisons between generalists and specialists other than cardiologists are
relatively scarce.  This was somewhat surprising in the case of endocrinologists,
given the enormous public health burden of diabetes.  The Medical Outcomes
Study found no significant differences in mean glycosylated hemoglobin
(“HgA1C”) levels, blood pressure control, or annual mortality rates between
the patients of internists, FPs, and endocrinologists.112  Marshall Chin and his
colleagues reported similar equivalency between physician types—with respect
to HgA1C, lipid testing, and retinal exams—for a diabetic population at an aca-
demic medical center.113  In another article, however, Chin and his colleagues
observed that patients of endocrinologists had higher utilization of ophthalmo-
logic screening, lipid testing, and glycosylated hemoglobin measurement than
those of generalists.114  Jennifer Zgibor and her colleagues replicated these
results for HgA1C and reported lower marker levels among subjects seen by
specialists.115  Jennifer Lafata and her colleagues discovered that diabetics whose
care was shared by generalists and endocrinologists were more likely to receive
disease-related preventive health services than the patients of either type of
doctor alone.116  The last two studies—with hundreds and thousands of patients
assigned to the specialist category—were the only ones with enough observa-
tions to detect clinically significant differences between comparison groups.
110. Go et al., supra note 98, at 225.
111. Id.
112. See Sheldon Greenfield et al., Outcomes of Patients with Hypertension and Non-Insulin-
Dependent Diabetes Mellitus Treated by Different Systems and Specialties: Results from the Medical
Outcomes Study, 274 JAMA 1436 (1995).  The Medical Outcomes Study followed chronically ill
patients—with hypertension, diabetes, AMI, CHF, or depression—over a four-year period in three
different cities.  Participants belonged to well-established HMOs or FFS plans.  See, e.g., Alvin R.
Tarlov et al., The Medical Outcomes Study: An Application of Methods for Monitoring the Results of
Medical Care, 262 JAMA 925, 926-28 (1989) (describing in detail the design of the Medical Outcomes
Study).
113. Marshall H. Chin et al., Variations in the Care of Elderly Persons with Diabetes Among
Endocrinologists, General Internists, and Geriatricians, 55 J. GERONTOLOGY 601 (2000).
114. Marshall H. Chin et al., Specialty Differences in the Care of Older Patients with Diabetes, 38
MED. CARE 131 (2000).
115. Janice C. Zgibor et al., The Association of Diabetes Specialist Care with Health Care Practices
and Glycemic Control in Patients with Type I Diabetes, 23 DIABETES CARE 472 (2000).
116. Jennifer E. Lafata et al., Provider Type and the Receipt of General and Diabetes-Related
Preventive Health Services Among Patients with Diabetes, 39 MED. CARE 491 (2001).
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C. Gynecologists
The performance of gynecologists (“GYNs”) relative to PCPs has also
received scant attention from clinical researchers.  Peter Curtis and his col-
leagues reported that GYNs, as a group, submitted a higher proportion of satis-
factory Pap smears to a commercial laboratory than generalists.117
Corroborating these results, Kevin Fiscella and Peter Franks found that Pap
smears performed by FPs more often lacked an endocervical component than
ones done by gynecologists.118  Karl Finison and his colleagues used over 186,000
Medicare Part B claims to conclude that women whose “usual care” physician
was a gynecologist had higher rates of mammography (seventy-eight percent)
than those treated primarily by internists (sixty-seven percent) or other doc-
tors.119  In a survey by Kathleen Torkko and her colleagues, generalists and
GYNs reported testing sexually active adolescent females equally often for
chlamydia.120  A survey by Laurel Desnick and her colleagues discovered that
FPs were less likely than GYNs to perform screening clinical breast examina-
tions in women aged fifty to seventy-five.121  Yet another survey found that gen-
eralists and GYNs recommended regular Pap smears and annual mammogra-
phy with equal frequency,122 though it concluded—from interviews with patients
as well as physicians—that GYNs more often suggested and succeeded in
obtaining Pap smears in women aged forty-five and older.123  Along similar lines,
a case-control study by David Celentano and his colleagues determined that
having seen a GYN at any point in a patient’s life protected against cervical
cancer (as did a recent visit to an internist).124
D. Summary
Though the quantity of the above evidence for gynecologists and endocri-
nologists is small, and its overall quality is poor, what was true for cardiologists
still seems true for these specialists: They appear to outperform generalists in
their field of expertise.  Nevertheless, even for cardiologists, this statement is
qualified by the paucity of outcome data and near absence of both prospective
117. Peter Curtis et al., Characteristics and Quality of Papanicolaou Smears Obtained by Primary
Care Clinicians Using a Single Commercial Laboratory, 8 ARCHIVES FAM. MED. 407 (1999).
118. Kevin Fiscella & Peter Franks, The Adequacy of Papanicolaou Smears as Performed by Family
Physicians and Obstetrician-Gynecologists, 48 J. FAM. PRAC. 294 (1999).
119. Karl S. Finison et al., Screening Mammography Rates by Specialty of the Usual Care Physician,
2 EFFECTIVE CLINICAL PRAC. 120 (1999).
120. Kathleen C. Torkko et al., Testing for Chlamydia and Sexual History Taking in Adolescent
Females: Results from a Statewide Survey of Colorado Primary Care Providers, 106 PEDIATRICS 32
(2000).
121. Laurel Desnick et al., Clinical Breast Examination in Primary Care: Perceptions and Predictors
Among Three Specialties, 8 J. WOMEN’S HEALTH 389 (1999).
122. See Carla J. Herman et al., Variation in Recommendations for Breast and Cervical Cancer
Screening Among Primary Care Physicians in North Carolina, 1991, 89 S. MED. J. 583 (1996).
123. Martha A. Teitelbaum et al., Specialty Differences in Physicians’ Recommendations in Relation
to Women’s Pap Testing Behavior, 26 MED. CARE 607 (1988).
124. David D. Celentano et al., Cervical Cancer Screening Practices Among Older Women: Results
from the Maryland Cervical Cancer Case-Control Study, 41 J. CLINICAL EPIDEMIOLOGY 531 (1988).
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studies and randomized trials in this review, although the result is plausible and
supported by some evidence.  It is not clear, however, that this conclusion rep-
resents an indictment of managed care.  The premise for this section has been
that gatekeeping prevents MCO members with specialized problems from
accessing the experts available to FFS patients.  But if, for example, PCPs in
MCOs regularly denied people with AMI or CHF the superior services of a
cardiologist, it should somehow be reflected in worse outcomes or process
measures for these enrollees.  Yet MCOs rival FFS in the quality of care for
cardiac cases, as demonstrated in the previous section and Table 1.  The same
holds true for most types of patients.  Gatekeeping’s potential for harm seems,
in fact, limited to theory.
IV
EVIDENCE FOR HARM: EARLY DISCHARGE AFTER DELIVERY
Early hospital discharge of mothers and newborns after delivery—a phe-
nomenon that antedated the ascendancy of managed care, but one embraced
and encouraged by MCOs as a cost-containment strategy—aroused fierce politi-
cal hostility in the 1990s, prompting passage of federal and state laws curtailing
its private enforcement.125  Though medical evidence apparently played little
role in the legislative debate,126 outcome studies on the effects of rapid postpar-
tum discharge are in fact available, most of which use maternal or neonatal
readmission as a surrogate endpoint for significant medical problems.127  It is of
interest to review this evidence to determine if there was indeed a scientific
basis for the statutory changes that were aimed at managed care.
Two systematic reviews have already been performed on the subject.  In
1995, Paula Braveman and her colleagues examined articles on early discharge
published between 1975 and 1994.128  They found serious methodological flaws
with the eighteen studies that examined maternity stays of less than forty-eight
hours, including a lack of appropriate comparison groups and “inadequate
description of participation criteria, protocols, or loss to follow-up.”129  The
three randomized trials in the review were not large enough to detect small but
clinically significant differences in maternal and neonatal outcomes.  Braveman
and her colleagues also called attention to the strict inclusion criteria of many
studies, which they believed limited their external validity.130  Kenneth Grullon
125. See, e.g., David A. Hyman, Drive-Through Deliveries: Is “Consumer Protection” Just What the
Doctor Ordered?, 78 N.C. L. REV. 5 (1999) (detailing the national, historical trend toward early
discharge and the success of the anecdote-driven campaign against it).
126. See id. at 20 (“Empirical studies casting light on the issue were ignored, and the debate was
driven by a handful of anecdotes.”).
127. See id. at 45-46.  Hyman argues that readmission is both overinclusive and underinclusive as an
endpoint, subject to both detection and selection bias.
128. Paula Braveman et al., Early Discharge of Newborns and Mothers: A Critical Review of the
Literature, 96 PEDIATRICS 716 (1995).
129. Id. at 724.  The eighteen studies presumably concerned vaginal delivery only.
130. See id. (noting the “stringent selection criterion” of the studies).
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and David Grimes published another literature analysis two years later, this one
capturing articles from 1966 through the beginning of 1997 (including two addi-
tional randomized, controlled trials).131  They too found fatal flaws with the
studies in their review, including self-selection bias, exclusion of patients after
randomization, and inadequate sample sizes.  “The evidence,” they wrote, “that
early postpartum discharge is as safe as traditional stay stems from cohort and
case-series studies with highly selected patients with extensive antepartum and
postpartum education and uncomplicated deliveries.”132  Like Braveman and her
colleagues, they were unable to render any evidence-based expert opinion on
the safety of routine rapid discharge.
More recently, the results of several well-designed studies on the risks of
short postpartum stays have been published.  Bruce Edmonson and his col-
leagues performed a case-control study in Wisconsin on neonatal readmissions
for feeding-related problems.133  They found that 210 cases were no more likely
than 630 controls to have been discharged within two days of delivery.  The
investigators adjusted their risk estimates for a variety of maternal and newborn
factors, including primiparity, birth weight, preterm status, and nursery feeding
type.134  Another case-control study, by Lenna Liu and her colleagues, chal-
lenged these findings.135  In this population-based analysis from Washington
State, 2029 cases (neonates rehospitalized within one month of birth) were
more likely than 8657 controls (newborns not readmitted) to have been dis-
charged within thirty hours of delivery.136  Liu and her colleagues adjusted their
results for multiple maternal and newborn characteristics as well.
In a commentary accompanying these two articles, Braveman and her col-
leagues sought to explain why studies with similar methodologies appeared to
have reached conflicting results.137  They observed that the Wisconsin study had
an insufficiently large sample to detect a difference as small as that reported by
131. Kenneth E. Grullon & David A. Grimes, The Safety of Early Postpartum Discharge: A Review
and Critique, 90 OBSTETRICS & GYNECOLOGY 860 (1997).  The authors limited themselves to studies
on hospital discharge within forty-eight hours after vaginal delivery, and within ninety-six hours after
cesarean delivery.  They examined a total of twenty-eight articles.
132. Id. at 864.
133. M. Bruce Edmonson et al., Hospital Readmission with Feeding-Related Problems After Early
Postpartum Discharge of Normal Newborns, 278 JAMA 299 (1997).  Cases comprised newborns
readmitted in the first month of life for feeding problems.  The authors hypothesized that early
discharge may jeopardize inpatient instruction of new mothers on breast-feeding and infant nutrition.
They thus chose feeding-related readmissions as their outcome measure.  The study cohort consisted of
singleton newborns delivered vaginally between 1991 and 1994, “having normal birth weights . . . and
continuous, uncomplicated stays at their birth hospitals until discharge on day one or two (early
discharge) or day three (conventional discharge).”  Id. at 299.
134. Id. at 301.
135. Lenna L. Liu et al., The Safety of Newborn Early Discharge: The Washington State Experience,
278 JAMA 293 (1997).
136. See id. at 296.  Odds ratio for rehospitalization at seven days: 1.28 with a confidence interval of
1.11 to 1.47; at fourteen days: 1.16 with a confidence interval of 1.03 to 1.32; at twenty-eight days: 1.12
with a confidence interval of 1.00 to 1.25.
137. Paula Braveman et al., Early Discharge and Evidence-Based Practice: Good Science and Good
Judgment, 278 JAMA 334 (1997).
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the Washington State investigators.138  They contended that this difference (a
higher risk of infant readmission of around 20% to 30%) may not seem enor-
mous, but that “because birth is such a common event, there is considerable
public health significance of a 20%, 10%, or even a 5% increased risk of serious
adverse events when it affects the entire maternal-newborn population.”139  It
also seems noteworthy that the two studies employed different outcome meas-
ures, and that their comparative results do not necessarily conflict.140
Two other studies published subsequent to Braveman and her colleagues’
commentary also merit mention.  Elizabeth Bragg and her colleagues reported
that neonatal readmission rates did not change at their institution after imple-
mentation of an early-discharge program for postpartum patients.141  Candidates
for discharge “were required to be free of medical complications, be physiologi-
cally stable, have no history of substance abuse, and be at least 18 years old or
have a stable and supportive environment at home.”142  They received home
visits from nurse clinicians, who conducted physical assessments of the mother
and child and provided education and lactation support.  The investigators did
not adjust their results for significant baseline differences between the (noncon-
temporanous) groups of infants, including birth weight and gestational age.143  In
addition, their study sample was only powered (at 80%) to detect a doubling of
the rate of readmission within the 1% to 2% range.144
Uma Kotagal and her colleagues conducted a much larger retrospective
cohort study—also with an historical control—using Medicaid claims data from
Ohio linked to vital statistics files.145  The authors observed a significant
decrease in the rehospitalization rate for neonates as the average length of
postpartum stay in the population fell from 2.2 days in 1991 to 1.6 days in
138. See Edmonson et al., supra note 133, at 300; see also Braveman et al., supra note 137, at 335
(stating that their sample size had 82% power to detect a true odds ratio (OR) of 1.6 or greater (at
alpha=.05).  Braveman and her colleagues calculated that this sample size had statistical power of only
32% to detect a true OR of 1.3 or greater (using the OR for rehospitalization at seven days in Liu’s
study as a reference).  See id. at 334.
139. Id. at 335.
140. For example, in a subgroup analysis, early discharge in the Liu study was not associated with a
significantly increased risk of rehospitalization for dehydration, one of the primary outcomes in
Edmonson’s study.  See Liu et al., supra note 135, at 296; see also Edmonson et al., supra note 133, at
300.
141. Elizabeth J. Bragg et al., The Effect of Early Discharge After Vaginal Delivery on Neonatal
Readmission Rates, 89 OBSTETRICS & GYNECOLOGY 930 (1997).  The authors enrolled 6267 vaginally
born infants in the study.  They calculated separate readmission rates for neonates discharged within
one hospital day and within twenty-four hours of delivery, neither of which differed from that of the
conventional discharge period group.  Readmission was defined as an admission occurring within ten
days of birth. Id.
142. Id. at 931.
143. See id. at 931-32.  The average birth weight of infants in the conventional-discharge group was
3086 grams, compared to 3209 grams for infants in the early-discharge group.
144. See id. at 932.
145. Uma R. Kotagal et al., Safety of Early Discharge for Medicaid Newborns, 282 JAMA 1150
(1999).  The study’s main outcome measures were rehospitalization within seven and fourteen days of
discharge.
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1995,146 and as the proportion of “short stays” rose from 21.0% to 59.8% of all
births.147  Their sample of 102,678 infants was powered (at 90%) to detect a 13%
difference in the rate of readmission (from 1.3% to 1.13%).148  In a multivariate
logistic regression model that controlled for maternal and neonatal characteris-
tics (many of which varied significantly over the course of the study period),
short stay was not associated with an increased risk of rehospitalization at either
seven or fourteen days after discharge.149  The investigators, however, noted an
annual increase in the proportion of newborns who received a primary care visit
within fourteen days of birth.150
The above study (like the one by Bragg and her colleagues) suffers from the
use of an historical control.  The readmission rate for neonates may have fallen
even further in Ohio if the average length of postpartum stay had not decreased
between 1991 and 1995.  Nevertheless, the analysis does provide some reassur-
ance that rapid discharge (with decent follow-up) did not result in the wholesale
slaughter of helpless infants, as some opponents of the practice seemed to sug-
gest.151  Based on Liu and her colleagues’ superior study from Washington State,
it is still possible that short stays are associated with a modest increase in the
risk of infant readmission, which—though important in itself—does not directly
translate into death or disability (or even harm).  It may be infeasible to con-
duct a randomized, controlled trial to provide conclusive evidence of the effects
of early discharge on readmissions.152  At this point, it would also be illegal, as
state and federal legislation mandating minimum forty-eight hour maternity
stays has rendered moot the legitimate medical debate over the safety of “drive-
through deliveries.”
V
CONCLUSION
The empirical evidence from the medical literature does not support the
allegations of unsafe practices made against MCOs by proponents of patient
protection legislation.  This finding holds despite data suggesting that general-
ists, who occupy a privileged position as gatekeepers in many MCOs, are less
proficient than specialists in the latter’s areas of expertise, because such a fact
does not appear to translate into worse specialty care for patients in managed
146. See id. at 1153-54.  Rehospitalization rates within seven days of discharge decreased by 23%,
from 1.3% in 1991 to 1.0% in 1995 (p=.01).  Rates within fourteen days of discharge decreased by 19%,
from 2.1% in 1991 to 1.7% in 1995 (p=.03).
147. See id. at 1151.  A “short stay” was defined as discharge within one day of vaginal delivery, and
two days of cesarean delivery.
148. Id. at 1155.
149. Id. at 1154-55.
150. Id. at 1153.
151. See, e.g., Hyman, supra note 125, at 81-86 (citing rash remarks by politicians on the supposed
dangers of early discharge).
152. See Braveman et al., supra note 137, at 335.  “At an underlying [neonatal] rehospitalization rate
of 2%, it would take at least 14,000 patients in each of 2 groups to detect a 25% increase in
rehospitalizations related to discharge timing.” Id.
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care plans.  This paper’s conclusion would be weakened if future studies con-
firmed the association between early postpartum discharge—a practice strongly
encouraged in the past by MCOs—and infant readmissions observed by investi-
gators from Washington State.  Though only a surrogate marker for harm (and
one of unknown long-term significance), rehospitalization of neonates is proba-
bly something best avoided, even at considerable cost to the health care system.
Nevertheless, sound reasons for increased regulation of MCOs may in fact
exist.  Consumer dissatisfaction with managed care has been well documented,153
and provisions in the law for such arrangements as direct access to medical spe-
cialists may well reflect the simple desire of the voting public.  The wishes of the
majority—even if arbitrary or harmful by empirical standards—should carry
weight in a democratic society.  It seems dishonest, however, for critics to claim
that the provisions of a patient’s bill of rights are necessary to protect the health
of MCO enrollees.  A substantive body of scientific evidence suggests that man-
aged care is as safe as the system it has replaced, its product as fit for popular
consumption as traditional, less affordable indemnity insurance.
153. See, e.g., Robert J. Blendon et al., Understanding the Managed Care Backlash, 17 HEALTH AFF.
July/Aug. 1998, at 80 (discussing the results of a nationwide survey on managed care).
